John Crowley

In this engaging conversation, John Crowley, CEO of the industry lobbying group BIO, discusses pressing issues in biotechnology. He sheds light on recent FDA layoffs and the implications for vaccine approval, particularly regarding Novavax's COVID-19 vaccine. Crowley addresses the critical need for a $15 billion federal investment to bolster U.S. biotech against competition from China. He also touches on the complexities surrounding public trust in science, the impact of tariffs on the industry, and how to navigate dialogues with controversial figures like RFK Jr.

John Crowley, BIO’s president and CEO, offers a policy lens as he discusses U.S.–China biotech competition, the need to balance innovation with patient access, and FDA consistency and modernization. He addresses MFN risks, vaccine hesitancy amid a measles resurgence, major China investments, and recent industry deal dynamics and clinical holds.